Physician profile
Frederick Ast
NPI 1699742288
$20,560.58
in general payments reported to CMS, 2019-2025
51 companies · $2,986 in 2025
The $2,986 reported for 2025 was more than what 77% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,691 · 2020: $3,120 · 2021: $3,329 · 2022: $2,968 · 2023: $2,541 · 2024: $1,925 · 2025: $2,986.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,250 · Consulting Fee: $110 · Education: $90.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,250.17 |
| Consulting Fee | $110.00 |
| Education | $90.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,360.61 | 2019-2025 | Benlysta, Trelegy Ellipta, Nucala |
| Amgen INC. | $2,320.94 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Janssen Biotech, INC. | $1,805.70 | 2019-2025 | Tremfya, Simponi, Remicade |
| Pfizer INC. | $1,663.28 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,364.36 | 2019-2025 | |
| Horizon Therapeutics Plc | $1,001.51 | 2019-2023 | Pennsaid |
| Ucb, INC. | $999.32 | 2019-2025 | Bimzelx, Cimzia |
| Mallinckrodt Hospital Products INC. | $940.93 | 2020-2025 | Acthar |
| Csl Behring | $929.77 | 2019-2025 | Haegarda, Kcentra |
| Astrazeneca Pharmaceuticals LP | $920.63 | 2019-2025 | Saphnelo, Farxiga, Tezspire |
| Lilly USA, LLC | $732.36 | 2019-2025 | Taltz |
| Genzyme Corporation | $724.58 | 2019-2025 | |
| Abbvie INC. | $458.43 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $420.78 | 2019-2024 | Dupixent |
| Genentech USA, INC. | $295.90 | 2019-2024 | Actemra |
Show all 47 companies
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Ast listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.